drugset / Trial / NCT00826163

Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00826163

Non-randomizedParallel-groupOpen-labelTreatment

Summary

We hypothesize that ongoing and more severe airway inflammation in COPD may result from the impairment in activation of innate immune response

Timeline

Start
2009-01
Primary completion
2009-11
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule 400 ug Inhaled